EVISA - Who we are
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
adverse health effect
A change in body function or cell structure that might lead to disease or health problems.
ATSDR Glossary of Terms
The term "adverse health effect" was found in the following pages:
FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs | EVISA's News
Link database: CDC: Biomonitoring Summary: Molybdenum
Link database: CDC: Biomonitoring Summary: Antimony
See the complete list of deadlines!
ISABC15: 15th International Symposium on Applied Bioinorganic Chemistry
CSI XLI: Colloqium Spectroscopicum Internationale XLI
Mexico City, Mexico
ReMiND 2019: Biomolecules in Neurodegenerative Diseases
Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
... more Events
What's new on EVISA's web site ?
Selenoneine is a major selenium species in red blood cells of Inuit from Nunavik
U.K. issues new advice on the use of gadolinium-based contrast agents
Scientists discover new broad-spectrum antibiotic based on arsenic
France to ban titanium dioxide whitener in food from 2020
... more News
You have forgotten your password ?
© 2003 - 2010 by European Virtual Institute for Speciation Analysis ( EVISA )